UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 12, 2005

 

EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)

 

Delaware

1-15525

36-4316614

(State or other jurisdiction
of incorporation)

(Commission
file number)

(IRS Employer
Identification No.)

 

 

 

One Edwards Way, Irvine, California

92614

(Address of principal executive offices)

(Zip Code)

 

(949) 250-2500

Registrant’s telephone number, including area code

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                    Pre-Commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                    Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

ITEM 1.01.                                    ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

 

On May 12, 2005, an amendment and restatement of the Edwards Lifesciences Corporation (the “Company”) Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”) was approved by the Company’s stockholders.  The Long-Term Stock Program had been approved by the Board of Directors on February 17, 2005, subject to stockholder approval.

 

The Long-Term Stock Program was amended and restated to effect the following changes:  (i) increase the number of shares of common stock available for issuance under the Long-Term Stock Program by 1,400,000 shares, from 15,500,000 shares to 16,900,000 shares; (ii) eliminate the Company’s ability to award performance shares and performance units; (iii) increase the number of shares of common stock that may be issued in the form of restricted stock or restricted stock units from 500,000 shares to 1,000,000 shares; (iv) increase the number of shares for which any one participant may be granted restricted stock and restricted stock units in any one fiscal year from 50,000 to 200,000 shares; (v) expand the performance criteria that the Compensation and Governance Committee of the Board of Directors may utilize in establishing specific targets to be attained as a condition to the vesting of one or more restricted stock issuances or restricted stock units under the Long-Term Program to qualify the compensation attributable to those issuances or units as performance-based compensation for purposes of Section 162(m) of the Internal Revenue Code.  A copy of the Long-Term Stock Program is attached as Exhibit 10.

 

Item 9.01.                                          Financial Statements and Exhibits.

 

(c)                                  Exhibits

 

Exhibit
Number

 

Description

 

 

 

10

 

Long-Term Stock Incentive Compensation Program (Amended and Restated as of February 17, 2005).

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: May 17, 2005

 

 

 

 

 

 

 

 

 

EDWARDS LIFESCIENCES CORPORATION

 

 

 

 

 

 

 

By:

/s/ Jay P. Wertheim

 

 

 

Jay P. Wertheim

 

 

Vice President, Associate General Counsel

 

 

and Secretary

 

3



 

Exhibit Index

 

Exhibit
Number

 

Description

 

 

 

10

 

Long-Term Stock Incentive Compensation Program (Amended and Restated as of February 17, 2005).

 

4